» Articles » PMID: 11752103

Organ Distribution of Multidrug Resistance Proteins 1, 2, and 3 (Mrp1, 2, and 3) MRNA and Hepatic Induction of Mrp3 by Constitutive Androstane Receptor Activators in Rats

Overview
Specialty Pharmacology
Date 2001 Dec 26
PMID 11752103
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Many phase I and II microsomal enzyme inducers share common mechanisms of transcriptional activation and thus share a similar battery of genes that are coordinately regulated. Many phase II metabolites are thought to be transported out of cells by multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3). The purpose of this study was to determine the organ distribution of these three transporters in rat, and whether they are coordinately regulated with phase I and II drug-metabolizing enzymes. Therefore, Mrp1, 2, and 3 mRNAs were quantified using branched DNA signal amplification in multiple tissues and in tissues from rats that were treated with 18 chemicals thought to induce drug-metabolizing enzymes by six different transcription activation mechanisms [aryl-hydrocarbon receptor ligands, constitutive androstane receptor (CAR) activators, pregnane-X-receptor ligands, peroxisome proliferator activator receptor ligands, electrophile response element (EpRE) activators, and CYP2E1 inducers]. It was found that Mrp1 was expressed at a high level in kidney, lung, intestine, and brain, with low expression in liver. Mrp2 was highly expressed in liver and duodenum, and Mrp3 was highly expressed throughout the intestine but very low in liver. Microsomal enzyme inducers did not markedly increase the expression of Mrp1 or Mrp2. However, Mrp3 expression was significantly increased by each of the CAR activators and an EpRE activator in liver. Mrp3 was not similarly induced in kidney and large intestine, demonstrating that the coordinate inducibility of Mrp3 is specific to the liver. We conclude that rat hepatic Mrp3 is induced by CAR activators, thus enhancing the vectoral excretion of some phase II metabolites from the liver to the blood.

Citing Articles

All Blood Brain Barrier Cell Types Demonstrate Capability to Influence Differential Tenofovir and Emtricitabine Metabolism and Transport in the Brain.

Wilkins H, Knerler S, Warshanna A, Colon Ortiz R, Haas K, Orsburn B ACS Pharmacol Transl Sci. 2024; 7(11):3626-3640.

PMID: 39539261 PMC: 11555524. DOI: 10.1021/acsptsci.4c00510.


Drug Metabolism and Transport Capacity of Endothelial Cells, Pericytes, and Astrocytes: Implications for CNS Drug Disposition.

Wilkins H, Knerler S, Warshanna A, Colon Ortiz R, Haas K, Orsburn B bioRxiv. 2024; .

PMID: 39149336 PMC: 11326144. DOI: 10.1101/2024.08.01.606165.


Developmental differences in the expression of ABC transporters at rat brain barrier interfaces following chronic exposure to diallyl sulfide.

Koehn L, Dziegielewska K, Mollgard K, Saudrais E, Strazielle N, Ghersi-Egea J Sci Rep. 2019; 9(1):5998.

PMID: 30979952 PMC: 6461637. DOI: 10.1038/s41598-019-42402-8.


Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis.

de Haan L, van der Lely S, Warps A, Hofsink Q, Olthof P, de Keijzer M J Clin Transl Res. 2019; 4(1):1-46.

PMID: 30761355 PMC: 6370335. DOI: 10.18053/jctres.04.201801.001.


New Insights in Genetic Cholestasis: From Molecular Mechanisms to Clinical Implications.

Sticova E, Jirsa M, Pawlowska J Can J Gastroenterol Hepatol. 2018; 2018:2313675.

PMID: 30148122 PMC: 6083523. DOI: 10.1155/2018/2313675.